Global & Public Health (all articles)
Nurse Home Visiting and Maternal Mental Health: 3-Year Follow-Up of a Randomized Trial
26 Jan, 2021 | 00:42h | UTCNurse Home Visiting and Maternal Mental Health: 3-Year Follow-Up of a Randomized Trial – Pediatrics (link to abstract – $ for full-text)
Covid-19 vaccine tracker: The global race to vaccinate
26 Jan, 2021 | 00:59h | UTCCovid-19 vaccine tracker: the global race to vaccinate – Financial Times
See also: Coronavirus (COVID-19) Vaccinations – Our World in Data
Commentary on Twitter
Israel appears to be the only country that was ready for the vaccines. https://t.co/MPCqNdzi97 pic.twitter.com/bTT8zDpDDF
— Julia Belluz (@juliaoftoronto) January 25, 2021
Report: UK variant of Coronavirus possibly more deadly
26 Jan, 2021 | 00:58h | UTCNERVTAG paper on COVID-19 variant of concern B.1.1.7
Commentaries: Coronavirus: UK variant ‘may be more deadly’ – BBC AND CDC reviewing new data that suggests coronavirus variant identified in UK could be more deadly – CNN
Why scientists are more worried about the Covid-19 variant discovered in South Africa
26 Jan, 2021 | 00:56h | UTCWhy scientists are more worried about the Covid-19 variant discovered in South Africa – Vox
Original study (preprint and commentaries): South African COVID-19 variant escapes neutralization by antibodies in COVID-19 convalescent plasma
See also: Fast-spreading COVID variant can elude immune responses – Nature
Commentary on Twitter
Hot off the preprint press: Another new study, from the excellent @rjlessells @Tuliodna, used live virus to show that South Africa #coronavirus 501Y.V2 can in vitro escape antibody response from prior infectionhttps://t.co/mrryWtnXUu
Context here: https://t.co/V6WVSbUQGk
— Julia Belluz (@juliaoftoronto) January 22, 2021
Moderna COVID-19 vaccine may be less effective against variant found in South Africa
26 Jan, 2021 | 00:54h | UTCModerna Finds COVID-19 Vaccine Less Effective Against Variant Found In South Africa – NPR
Moderna Press release: Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa
See also: Expert reaction to preprint from Moderna about neutralising activity of their vaccine against new variants and announcement of plans to trial a variant booster jab targeting the South African (B.1.351) variant – Science Media Centre AND Moderna Launches Trial For Covid-19 Vaccine Booster To Tackle South African Strain – Forbes
Commentary on Twitter
🔥Moderna preprint PUBLISHED🔥
A six-fold reduction in neutralizing titers was observed with B.1.351 variant relative to prior variants Despite this reduction, neutralizing titer levels with B.1.351 remain above levels that are expected to be protective https://t.co/pDfgRn6Ost pic.twitter.com/VLu3iOqAda— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) January 25, 2021
New analysis does not support a major role of school reopening in the second COVID-19 wave in Israel
26 Jan, 2021 | 00:52h | UTC
Commentary on Twitter
Very interesting paper
Despite previous certainty about schools being the driving factor in the second wave in Israel, now looks unlikely
Easing restrictions of large gatherings in adults the predominant factor
Young adults, not children, as elsewherehttps://t.co/oWHbZynRpL
— Alasdair Munro (@apsmunro) January 25, 2021
UNICEF Executive Director Statement: “Children cannot afford another year of school disruption”
26 Jan, 2021 | 00:53h | UTCChildren cannot afford another year of school disruption – UNICEF
Commentary on Twitter
"Children cannot afford another year of school disruption."
Statement by UNICEF Executive Director @unicefchief Henrietta H. Fore
Find out more 👉https://t.co/DwuaHGub3B pic.twitter.com/jQbdLK2EE5
— UNICEF Rwanda (@unicefrw) January 13, 2021
German study provides evidence that opening schools may be safe
26 Jan, 2021 | 00:51h | UTCGerman Study Provides Evidence that Opening Schools May Be Safe – Physician’s Weekly
Original Study: Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany – JAMA Pediatrics
Editorial: To Spread or Not to Spread SARS-CoV-2—Is That the Question?
Related: Three studies highlight low COVID risk of in-person school
WHO COVAX Announces new agreement, plans for first deliveries
26 Jan, 2021 | 00:49h | UTCCOVAX Announces new agreement, plans for first deliveries – World Health Organization
Commentary on Twitter
#COVAX has signed an agreement with Pfizer/BioNTech for up to 40M doses of its #COVID19 vaccine.
We also expect to distribute almost 150M doses of the AstraZeneca/Oxford vaccine in the 1/4 of 2021, once the vaccine is listed for emergency use by @WHO. https://t.co/yx3FFl9bv8— Tedros Adhanom Ghebreyesus (@DrTedros) January 23, 2021
Global incidence and mortality of neonatal sepsis: A systematic review and meta-analysis
25 Jan, 2021 | 01:22h | UTC
Global variation in postoperative mortality and complications after cancer surgery: a multicenter, prospective cohort study in 82 countries
25 Jan, 2021 | 01:21h | UTCCommentary: Better post-surgical care would boost cancer survival chances – University of Birmingham
Commentary on Twitter (thread – Click for more)
https://twitter.com/ewenharrison/status/1352401851711418372
[Press Release – Not Published Yet] Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients
25 Jan, 2021 | 01:43h | UTCStudy Protocol: Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19) – ClinicalTrials.gov
“Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days.”
Commentaries: ‘Major breakthrough’ | Large study shows effectiveness of colchicine to treat COVID-19 – The Canadian AND A gout drug shows promise for Covid-19, but skeptics worry about trusting science by press release – STAT
Commentary on Twitter
Press release 🔥 #colchicine decreased ⬇️
🏥 hospitalizations 25%
🤕 use of ventilation 50%
💀 mortality 44%
in multinational trial of >4,000 non-hospitalized #COVID patientsMore: https://t.co/htMRdParq3
Full report awaited…@EricTopol @DrEricDing @MartinLandray #EBM pic.twitter.com/iodiEJBtV1
— Kari Tikkinen (@KariTikkinen) January 23, 2021
Revisiting the UK’s strategy for delaying the second dose of the Pfizer covid-19 vaccine
25 Jan, 2021 | 01:32h | UTC
Commentary on Twitter
These new data suggest that the UK govt should reconsider the decision to delay the second dose of the Pfizer/BioNTech vaccine. If they are determined to continue with the delayed second dose, then a robust randomized evaluation is urgently required https://t.co/4xrBFwZWkN
— The BMJ (@bmj_latest) January 24, 2021
Systematic review: At least one third of SARS-CoV-2 infections are asymptomatic
25 Jan, 2021 | 01:33h | UTCCommentary from the authors: The day we let Covid-19 spin out of control – STAT
Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline
25 Jan, 2021 | 01:35h | UTCOriginal Guideline: COVID-19 rapid guideline: managing the long-term effects of COVID-19 – National Institute for Health and Care Excellence
Airborne transmission of SARS-CoV-2: What we know
22 Jan, 2021 | 08:38h | UTCAirborne Transmission of SARS-CoV-2: What We Know – Clinical Infectious Diseases
Commentary on Twitter
Our workshop summary on airborne transmission of SARS-CoV-2 is out. Thanks to all the leading scientists who helped lead this amazing and impactful workshop! @theNASEM @linseymarr @kprather88 @Lakdawala_Lab https://t.co/MKfNA0QatN
— John Volckens (@Smogdr) January 18, 2021
Perspective: Vaccinating children against Covid-19 — the lessons of measles
22 Jan, 2021 | 08:34h | UTCVaccinating Children against Covid-19 — The Lessons of Measles – New England Journal of Medicine
Patients, clinicians seek answers to the mystery of ‘Long COVID’
22 Jan, 2021 | 08:32h | UTCPatients, clinicians seek answers to the mystery of ‘Long COVID’ – CIDRAP
Ten recommendations to improve pharmacy practice in low and middle-income countries
22 Jan, 2021 | 08:21h | UTC
‘A bloody mess’: Confusion reigns over naming of new COVID variants
21 Jan, 2021 | 01:27h | UTC‘A bloody mess’: Confusion reigns over naming of new COVID variants – Nature
[Preprint] South African COVID-19 variant escapes neutralization by antibodies in COVID-19 convalescent plasma
21 Jan, 2021 | 01:28h | UTCSARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma – bioRxiv
Commentaries: Expert reaction to preprint reporting that the South African SARS-CoV-2 variant 501Y.V2 escapes neutralisation by COVID-19 donor plasma – Science Media Centre AND S.Africa virus strain poses ‘re-infection risk’: study – MedicalXpress
5 reasons to wear a mask even after you’re vaccinated
21 Jan, 2021 | 01:24h | UTC5 Reasons to Wear a Mask Even After You’re Vaccinated – Kaiser Health News
Vaccinology in the post−COVID-19 era
21 Jan, 2021 | 01:24h | UTCVaccinology in the post−COVID-19 era – Proceedings of the National Academy of Sciences
Allocating scarce intensive care resources during the COVID-19 pandemic: practical challenges to theoretical frameworks
21 Jan, 2021 | 01:22h | UTC
COVID-19 testing: One size does not fit all
21 Jan, 2021 | 01:21h | UTCCOVID-19 testing: One size does not fit all – Science
Commentary on Twitter
COVID-19 testing: One size does not fit all https://t.co/zduxAcrMAA An excellent article by @michaelmina_lab and Kristian Andersen discussing the differences between diagnostic testing, surveillance testing and screening testing.
— Carlos del Rio (@CarlosdelRio7) January 8, 2021